Pulmocide Ltd has raised $30.4 million to clinically develop its inhaled therapies to treat respiratory syncytial virus (RSV) and pulmonary aspergillosis.
Pulmocide is on track to deliver proof of concept data in RSV with its highly potent inhaled RSV antiviral agent (PC786) in human RSV challenge and in infants hospitalized with bronchiolitis due to RSV infection.
Pulmocide will also be progressing PC945, a potent azole antifungal for the treatment of pulmonary Aspergillosis, including fungal asthma, pulmonary Aspergilloma, Aspergillus infections in lung transplant recipients and patients with cystic fibrosis.
“Respiratory infections are a significant cause of global morbidity and mortality with a high unmet medical need. Pulmocide is developing bespoke inhaled medicines to provide effective and safe therapies for the treatment of RSV and pulmonary Aspergillosis.” said Dr Garth Rapeport, CEO of Pulmocide.
“This Series B fundraising will provide us with the capital to advance our two novel compounds through early clinical development; another step closer to a treatment for patients for these debilitating infections. We are delighted by the interest we’ve received in this round and would like to thank our new and existing shareholders for their support and continued commitment to Pulmocide. We look forward to providing further pipeline updates as developments progress with our important programs.”
